CVS Health Corporation $CVS Shares Acquired by Hamlin Capital Management LLC

Key Points

• Hamlin Capital Management increased its CVS Health position by 4.6% in the second quarter, purchasing 74,962 additional shares to own 1.72 million shares valued at approximately $177.7 million. Institutional investors collectively own 80.66% of CVS.
• Analysts maintain a bullish outlook, with 21 Buy ratings and three Holds producing a “Moderate Buy” consensus and an average price target of $105.67.
• CVS reported quarterly EPS of $2.58, beating expectations, while revenue rose 7.3% to $106.1 billion. The company raised its fiscal 2026 EPS guidance to $7.90–$8.10 and increased operating cash-flow guidance to at least $11.5 billion.

Hamlin Capital Management LLC boosted its position in CVS Health Corporation (NYSE:CVS - Free Report) by 4.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,717,608 shares of the pharmacy operator's stock after purchasing an additional 74,962 shares during the period. CVS Health comprises 4.0% of Hamlin Capital Management LLC's investment portfolio, making the stock its 11th biggest position. Hamlin Capital Management LLC owned approximately 0.13% of CVS Health worth $177,687,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of CVS. State Street Corp lifted its position in CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the period. Legal & General Group Plc grew its holdings in CVS Health by 0.3% in the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator's stock valued at $738,777,000 after buying an additional 31,249 shares during the period. Deutsche Bank AG increased its stake in shares of CVS Health by 28.4% during the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator's stock valued at $370,333,000 after acquiring an additional 1,031,998 shares during the last quarter. KBC Group NV increased its stake in shares of CVS Health by 200.4% during the 4th quarter. KBC Group NV now owns 676,809 shares of the pharmacy operator's stock valued at $53,711,000 after acquiring an additional 451,521 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new position in shares of CVS Health during the 4th quarter worth about $3,333,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CVS shares. Sanford C. Bernstein lifted their price target on shares of CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a report on Tuesday, May 12th. Piper Sandler reaffirmed an "overweight" rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. JPMorgan Chase & Co. lifted their target price on CVS Health from $101.00 to $111.00 and gave the company an "overweight" rating in a report on Tuesday, May 12th. Argus boosted their price target on CVS Health from $90.00 to $104.00 and gave the company a "buy" rating in a research report on Thursday, May 14th. Finally, Weiss Ratings upgraded CVS Health from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, July 20th. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $105.67.

CVS Health Stock Performance

NYSE:CVS opened at $99.24 on Thursday. CVS Health Corporation has a twelve month low of $62.52 and a twelve month high of $110.68. The firm has a market capitalization of $126.62 billion, a price-to-earnings ratio of 43.72, a PEG ratio of 1.02 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm's fifty day simple moving average is $102.10 and its 200 day simple moving average is $87.56.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. CVS Health's payout ratio is 117.18%.

Insider Transactions at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the firm's stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 in the last three months. 0.85% of the stock is currently owned by company insiders.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Strong quarterly beat: CVS reported adjusted EPS of $2.58, well above the roughly $1.86–$1.87 consensus, while revenue rose 7.3% year over year to $106.1 billion, exceeding estimates near $100 billion. All three major segments—insurance, pharmacy and health services—reportedly surpassed revenue expectations. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: Insurance turnaround is showing progress: Lower-than-expected medical costs and improved performance at Aetna helped drive the profit increase, while better-rated government health plans generated bonus payments. A more profitable pharmacy drug mix also supported results. CVS raises annual profit forecast on improved drug revenues
• Positive Sentiment: Guidance and cash flow increased: CVS raised 2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50 and lifted operating cash-flow guidance to at least $11.5 billion from $9.5 billion. CVS Health reports strong second quarter results and raises full-year guidance
• Positive Sentiment: GLP-1 opportunity expanded: A new collaboration with Eli Lilly will broaden CVS’s direct-to-consumer weight-management services and access to Zepbound and other GLP-1 medications, potentially creating additional pharmacy and care-service revenue. CVS enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: Despite the earnings beat, CVS’s valuation and recent rally may have raised investor expectations, making the market more sensitive to cautious commentary and execution risks.
• Negative Sentiment: Management remarks concerning the PBM unit reportedly prompted the initial gains to reverse. Investors may be concerned about Caremark’s competitive, pricing and margin outlook, limiting enthusiasm for the higher guidance. CVS Health reverses early gains after management remarks on PBM unit

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source